Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries 4D Molecular Therapeutics Inc (NQ: FDMT ) 8.350 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EST, Nov 6, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about 4D Molecular Therapeutics Inc < Previous 1 2 3 4 5 6 7 Next > 12 Health Care Stocks Moving In Monday's Pre-Market Session February 05, 2024 Via Benzinga Why 4D Molecular Therapeutics Shares Are Trading Higher By 20%; Here Are 20 Stocks Moving Premarket February 05, 2024 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) rose sharply in today’s pre-market trading. 4DMT presented interim data from randomized Phase 2 PRISM clinical trial of intravitreal 4D-150... Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday February 05, 2024 The biggest pre-market stock movers are starting off the trading week as we check out all of the hottest news for Monday morning! Via InvestorPlace What 6 Analyst Ratings Have To Say About 4D Molecular Therapeutics July 31, 2023 Via Benzinga Analyst Ratings for 4D Molecular Therapeutics July 05, 2023 Via Benzinga Analyst Ratings for 4D Molecular Therapeutics June 08, 2023 Via Benzinga 4DMT Presents Positive Interim Data from Randomized Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 Demonstrating Favorable Tolerability & Clinical Activity in Wet AMD February 03, 2024 From 4D Molecular Therapeutics, Inc. Via GlobeNewswire 4DMT to Host Corporate Webcast to Discuss Interim Data from Phase 2 PRISM Clinical Trial of Intravitreal 4D-150 in Wet AMD Patients with Severe Disease Activity & High Treatment Burden January 29, 2024 From 4D Molecular Therapeutics, Inc. Via GlobeNewswire 4DMT Receives Rare Pediatric Disease Designation from FDA for Aerosolized 4D-710 for Treatment of Cystic Fibrosis Lung Disease January 23, 2024 From 4D Molecular Therapeutics, Inc. Via GlobeNewswire 4DMT Highlights Recent Clinical Pipeline Progress, Near-Term Milestones and Organizational Updates January 04, 2024 From 4D Molecular Therapeutics, Inc. Via GlobeNewswire 4DMT and Arbor Biotechnologies Establish Partnership to Co-Develop and Co-Commercialize Next-Generation Genetic Medicines for CNS Diseases January 03, 2024 From 4D Molecular Therapeutics, Inc. Via GlobeNewswire Why CarMax Shares Are Trading Higher By Around 8%? Here Are Other Stocks Moving In Thursday's Mid-Day Session December 21, 2023 Shares of CarMax, Inc. (NYSE: KMX) moved higher during Thursday’s session following better-than-expected quarterly earnings. Via Benzinga 4DMT Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for 4D-150 Genetic Medicine for Intravitreal Treatment of Wet AMD, the First RMAT Designation in Wet AMD December 21, 2023 From 4D Molecular Therapeutics, Inc. Via GlobeNewswire 4DMT to Present Interim 24 Week Data from Randomized Phase 2 PRISM Clinical Trial of 4D-150 in High Treatment Need Wet AMD Patients at Angiogenesis, Exudation, and Degeneration 2024 Conference December 04, 2023 From 4D Molecular Therapeutics, Inc. Via GlobeNewswire 4DMT to Participate in Upcoming Investor Conferences November 15, 2023 From 4D Molecular Therapeutics, Inc. Via GlobeNewswire 4DMT Reports Third Quarter 2023 Financial Results and Operational Highlights November 09, 2023 From 4D Molecular Therapeutics, Inc. Via GlobeNewswire 4DMT Presents Positive Interim Data from Phase 1/2 AEROW Clinical Trial of Aerosolized 4D-710 for Cystic Fibrosis at 2023 NACFC November 01, 2023 From 4D Molecular Therapeutics, Inc. Via GlobeNewswire 4DMT Gains Alignment with FDA on Plan to Lift Clinical Hold on Phase 1/2 INGLAXA Clinical Trial for 4D-310 for Fabry Disease Cardiomyopathy October 30, 2023 From 4D Molecular Therapeutics, Inc. Via GlobeNewswire 4DMT to Present Interim Data from Aerosolized 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis at 2023 NACFC October 25, 2023 From 4D Molecular Therapeutics, Inc. Via GlobeNewswire 4DMT Receives EMA Priority Medicines (PRIME) Designation for 4D-150 Clinical-Stage Genetic Medicine for Treatment of Wet AMD October 23, 2023 From 4D Molecular Therapeutics, Inc. Via GlobeNewswire Abbott Laboratories, Nasdaq, Spirit AeroSystems And Other Big Stocks Moving Higher On Wednesday October 18, 2023 U.S. stocks traded lower, with the Dow Jones falling around 50 points on Wednesday. Here are some big stocks recording gains in today’s session. Via Benzinga Topics Stocks Exposures US Equities 12 Health Care Stocks Moving In Wednesday's After-Market Session September 20, 2023 Via Benzinga 4DMT Appoints Uneek Mehra as Chief Financial and Business Officer September 12, 2023 From 4D Molecular Therapeutics, Inc. Via GlobeNewswire 4DMT to Participate in Upcoming Investor Conferences September 07, 2023 From 4D Molecular Therapeutics, Inc. Via GlobeNewswire 4DMT Announces First Patient Enrolled in 4D-150 Phase 2 SPECTRA Clinical Trial in DME, and Expansion of 4D-150 Phase 2 Stage in PRISM Clinical Trial in Wet AMD September 07, 2023 From 4D Molecular Therapeutics, Inc. Via GlobeNewswire 4D Molecular Therapeutics Reports Second Quarter 2023 Financial Results and Operational Highlights August 09, 2023 From 4D Molecular Therapeutics, Inc. Via GlobeNewswire 4DMT Presents Additional Positive Interim Data from Intravitreal 4D-150 Phase 1/2 PRISM Clinical Trial in Patients with Wet AMD at ASRS 2023 July 29, 2023 From 4D Molecular Therapeutics, Inc. Via GlobeNewswire 4DMT Completes Enrollment of Phase 2 PRISM Clinical Trial for Intravitreal 4D-150 in Patients with Wet AMD and Reports Interim Safety and Tolerability Data July 17, 2023 From 4D Molecular Therapeutics, Inc. Via GlobeNewswire 4D Molecular Poised For Success: FDA Discussion And Solid Position In Competitive Genetic Medicine Space, Says Analyst July 05, 2023 Chardan Research analyst Geulah Livshits initiated coverage on 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) with a Buy rating and Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For July 5, 2023 July 05, 2023 Via Benzinga < Previous 1 2 3 4 5 6 7 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
